In summary, the detrimental effect of excessive SLC9A6‐126aa, which is encoded by circ‐SLC9A6, may be dependent mainly on the activation of CD36 transcription and the downstream MAPK signaling pathway during the development of NAFLD, which may lead to therapeutic targets for clinical therapy. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.